DK1447414T3 - Antagonistpeptider af carcinoembronisk antigen (CEA) - Google Patents

Antagonistpeptider af carcinoembronisk antigen (CEA)

Info

Publication number
DK1447414T3
DK1447414T3 DK04011673T DK04011673T DK1447414T3 DK 1447414 T3 DK1447414 T3 DK 1447414T3 DK 04011673 T DK04011673 T DK 04011673T DK 04011673 T DK04011673 T DK 04011673T DK 1447414 T3 DK1447414 T3 DK 1447414T3
Authority
DK
Denmark
Prior art keywords
cea
peptides
carcinoembryonic antigen
antigen antagonist
agonists
Prior art date
Application number
DK04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK1447414T3 publication Critical patent/DK1447414T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04011673T 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA) DK1447414T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10
PCT/US1998/019794 WO1999019478A1 (en) 1997-10-10 1998-09-22 Agonist and antagonist peptides of carcinoembryonic antigen (cea)

Publications (1)

Publication Number Publication Date
DK1447414T3 true DK1447414T3 (da) 2007-09-10

Family

ID=22036775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04011673T DK1447414T3 (da) 1997-10-10 1998-09-22 Antagonistpeptider af carcinoembronisk antigen (CEA)

Country Status (11)

Country Link
EP (1) EP1017810B1 (da)
JP (1) JP4291508B2 (da)
AT (2) ATE364048T1 (da)
AU (1) AU745863B2 (da)
CA (1) CA2308127C (da)
CY (1) CY1107706T1 (da)
DE (2) DE69837896T2 (da)
DK (1) DK1447414T3 (da)
ES (2) ES2217585T3 (da)
PT (1) PT1447414E (da)
WO (1) WO1999019478A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ATE449858T1 (de) * 1999-10-11 2009-12-15 Pasteur Institut Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
ATE395930T1 (de) * 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
CA2416893A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
US20060239962A1 (en) * 2002-12-04 2006-10-26 Banchereau Jacques F Rapid one-step generation of antigen loaded dendritic cell vaccine from precursors
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
EA018457B1 (ru) 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
CA2973109A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0584266T3 (da) * 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
EP1017810A1 (en) 2000-07-12
AU9500498A (en) 1999-05-03
ES2286530T3 (es) 2007-12-01
DE69824023D1 (de) 2004-06-24
DE69824023T2 (de) 2005-05-12
WO1999019478A1 (en) 1999-04-22
DE69837896T2 (de) 2008-02-14
JP4291508B2 (ja) 2009-07-08
ATE364048T1 (de) 2007-06-15
CA2308127A1 (en) 1999-04-22
PT1447414E (pt) 2007-07-18
AU745863B2 (en) 2002-04-11
EP1017810B1 (en) 2004-05-19
CY1107706T1 (el) 2013-04-18
JP2002500002A (ja) 2002-01-08
DE69837896D1 (de) 2007-07-19
ATE267213T1 (de) 2004-06-15
ES2217585T3 (es) 2004-11-01
CA2308127C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
PT935607E (pt) Proteinas de fusao de classe ii do cph soluveis monovalentes e multivalentes, e suas utilizacoes
NO923953D0 (no) Peptider
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
DE69533923D1 (de) Cytokinin-designiertes lerk-5
ATE458494T1 (de) Von der telomerase abgeleitete antigene peptide
GEP20074091B (en) Cripto blocking antibodies and uses thereof
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
MY109957A (en) Improved antibodies to plasmodium falciparum
DE69837283D1 (de) Verwendung von einem phospatidylserine/polypeptide konjugat um autoimmunität hervorzurufen in der behandlung von krebs
ATE217795T1 (de) Saponin-antigen-konjugate und ihre verwendung
IS5697A (is) Uppleysanlegur T-eitilfrumu viðtaki
GEP20105118B (en) Anti-vegf antibodies
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
PT1171143E (pt) Extracto peptidico de tremoco e composicao farmaceutica ou cosmetica ou nutraceutica compreendendo o referido extracto
CR8231A (es) Anticuerpos rg1 y uso de los mismos
IL142905A0 (en) Functional antagonists of hedgehog activity
FI933253A7 (fi) Uusia amyliiniantagonistipeptidejä ja käyttö amyliiniantagonisteina
IL145689A0 (en) Methods
EP1447414A3 (en) Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
ATE442387T1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
DE60045776D1 (de) Hla-bindungspeptide und ihre anwendungszwecke